New pill combo aims to crush bad cholesterol

NCT ID NCT07218900

First seen Nov 01, 2025

Summary

This study tests whether adding a new drug called AZD0780 to the common statin rosuvastatin can lower 'bad' LDL cholesterol more than rosuvastatin alone. About 76 adults with high cholesterol will take either AZD0780 or a placebo pill, plus rosuvastatin, for 12 weeks. Neither participants nor doctors know who gets the real drug until the study ends.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSLIPIDAEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Aramil, 624002, Russia

  • Research Site

    Ivanovo, 153012, Russia

  • Research Site

    Moscow, 105554, Russia

  • Research Site

    Moscow, 111539, Russia

  • Research Site

    Moscow, 117292, Russia

  • Research Site

    Moscow, 121552, Russia

  • Research Site

    Perm, 614000, Russia

  • Research Site

    Saint Petersburg, 194156, Russia

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

AZD0780 (a small molecule drug taken as a tablet) combined with rosuvastatin (a statin tablet)

What this could lead to

If it works, this could lead to a new combination treatment that lowers 'bad' cholesterol more effectively than statins alone.

What could go wrong

This is an early Phase 2 trial with only 76 people, so results may not apply to everyone. The drug may not lower cholesterol enough or could have side effects not yet seen.

Conditions

The condition(s) this trial relates to.

Dyslipidemias inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.